Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends

Muhammad Farhan Sohail,1–3 Mubashar Rehman,4,5 Hafiz Shoaib Sarwar,2 Sara Naveed,1 Omer Salman,6 Nadeem Irfan Bukhari,7 Irshad Hussain,3 Thomas J Webster,5 Gul Shahnaz21Riphah Institute of Pharmaceutical Sciences, Riphah International University, Lahore Campus, Lahore, 2Department of Pharm...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sohail MF, Rehman M, Sarwar HS, Naveed S, Salman O, Bukhari NI, Hussain I, Webster TJ, Shahnaz G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Anticancer permeability enhancement solubility enhancement p-glycoproteins efflux pump first pass metabolism Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/315cf62a23d74bb081c1d474a42970e4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:315cf62a23d74bb081c1d474a42970e4
record_format	dspace
spelling	oai:doaj.org-article:315cf62a23d74bb081c1d474a42970e42021-12-02T07:07:09ZAdvancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends1178-2013https://doaj.org/article/315cf62a23d74bb081c1d474a42970e42018-06-01T00:00:00Zhttps://www.dovepress.com/advancements-in-the-oral-delivery-of-docetaxel-challenges-current-stat-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Muhammad Farhan Sohail,1–3 Mubashar Rehman,4,5 Hafiz Shoaib Sarwar,2 Sara Naveed,1 Omer Salman,6 Nadeem Irfan Bukhari,7 Irshad Hussain,3 Thomas J Webster,5 Gul Shahnaz21Riphah Institute of Pharmaceutical Sciences, Riphah International University, Lahore Campus, Lahore, 2Department of Pharmacy, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, 3Department of Chemistry, SBA School of Science and Engineering (SBASSE), Lahore University of Management Sciences (LUMS), Lahore, 4Department of Pharmacy, University of Lahore-Gujrat Campus, Gujrat, 5Department of Chemical Engineering, Northeastern University, Boston, MA, USA; 6Department of Pharmacy, University of Lahore, Lahore Campus, 7University College of Pharmacy, University of the Punjab, Allama Iqbal Campus, Lahore, Pakistan Abstract: The oral delivery of cancer chemotherapeutic drugs is challenging due to low bioavailability, gastrointestinal side effects, first-pass metabolism and P-glycoprotein efflux pumps. Thus, chemotherapeutic drugs, including Docetaxel, are administered via an intravenous route, which poses many disadvantages of its own. Recent advances in pharmaceutical research have focused on designing new and efficient drug delivery systems for site-specific targeting, thus leading to improved bioavailability and pharmacokinetics. A decent number of studies have been reported for the safe and effective oral delivery of Docetaxel. These nanocarriers, including liposomes, polymeric nanoparticles, metallic nanoparticles, hybrid nanoparticles, dendrimers and so on, have shown promising results in research papers and clinical trials. The present article comprehensively reviews the research efforts made so far in designing various advancements in the oral delivery of Docetaxel. Different strategies to improve oral bioavailability, prevent first-pass metabolism and inhibition of efflux pumping leading to improved pharmacokinetics and anticancer activity are discussed. The final portion of this review article presents key issues such as safety of nanomaterials, regulatory approval and future trends in nanomedicine research. Keywords: anticancer, permeability enhancement, solubility enhancement, P-glycoproteins, efflux pump, first-pass metabolismSohail MFRehman MSarwar HSNaveed SSalman OBukhari NIHussain IWebster TJShahnaz GDove Medical PressarticleAnticancerpermeability enhancementsolubility enhancementp-glycoproteinsefflux pumpfirst pass metabolismMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 13, Pp 3145-3161 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Anticancer permeability enhancement solubility enhancement p-glycoproteins efflux pump first pass metabolism Medicine (General) R5-920
spellingShingle	Anticancer permeability enhancement solubility enhancement p-glycoproteins efflux pump first pass metabolism Medicine (General) R5-920 Sohail MF Rehman M Sarwar HS Naveed S Salman O Bukhari NI Hussain I Webster TJ Shahnaz G Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends
description	Muhammad Farhan Sohail,1–3 Mubashar Rehman,4,5 Hafiz Shoaib Sarwar,2 Sara Naveed,1 Omer Salman,6 Nadeem Irfan Bukhari,7 Irshad Hussain,3 Thomas J Webster,5 Gul Shahnaz21Riphah Institute of Pharmaceutical Sciences, Riphah International University, Lahore Campus, Lahore, 2Department of Pharmacy, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, 3Department of Chemistry, SBA School of Science and Engineering (SBASSE), Lahore University of Management Sciences (LUMS), Lahore, 4Department of Pharmacy, University of Lahore-Gujrat Campus, Gujrat, 5Department of Chemical Engineering, Northeastern University, Boston, MA, USA; 6Department of Pharmacy, University of Lahore, Lahore Campus, 7University College of Pharmacy, University of the Punjab, Allama Iqbal Campus, Lahore, Pakistan Abstract: The oral delivery of cancer chemotherapeutic drugs is challenging due to low bioavailability, gastrointestinal side effects, first-pass metabolism and P-glycoprotein efflux pumps. Thus, chemotherapeutic drugs, including Docetaxel, are administered via an intravenous route, which poses many disadvantages of its own. Recent advances in pharmaceutical research have focused on designing new and efficient drug delivery systems for site-specific targeting, thus leading to improved bioavailability and pharmacokinetics. A decent number of studies have been reported for the safe and effective oral delivery of Docetaxel. These nanocarriers, including liposomes, polymeric nanoparticles, metallic nanoparticles, hybrid nanoparticles, dendrimers and so on, have shown promising results in research papers and clinical trials. The present article comprehensively reviews the research efforts made so far in designing various advancements in the oral delivery of Docetaxel. Different strategies to improve oral bioavailability, prevent first-pass metabolism and inhibition of efflux pumping leading to improved pharmacokinetics and anticancer activity are discussed. The final portion of this review article presents key issues such as safety of nanomaterials, regulatory approval and future trends in nanomedicine research. Keywords: anticancer, permeability enhancement, solubility enhancement, P-glycoproteins, efflux pump, first-pass metabolism
format	article
author	Sohail MF Rehman M Sarwar HS Naveed S Salman O Bukhari NI Hussain I Webster TJ Shahnaz G
author_facet	Sohail MF Rehman M Sarwar HS Naveed S Salman O Bukhari NI Hussain I Webster TJ Shahnaz G
author_sort	Sohail MF
title	Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends
title_short	Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends
title_full	Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends
title_fullStr	Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends
title_full_unstemmed	Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends
title_sort	advancements in the oral delivery of docetaxel: challenges, current state-of-the-art and future trends
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/315cf62a23d74bb081c1d474a42970e4
work_keys_str_mv	AT sohailmf advancementsintheoraldeliveryofdocetaxelchallengescurrentstateoftheartandfuturetrends AT rehmanm advancementsintheoraldeliveryofdocetaxelchallengescurrentstateoftheartandfuturetrends AT sarwarhs advancementsintheoraldeliveryofdocetaxelchallengescurrentstateoftheartandfuturetrends AT naveeds advancementsintheoraldeliveryofdocetaxelchallengescurrentstateoftheartandfuturetrends AT salmano advancementsintheoraldeliveryofdocetaxelchallengescurrentstateoftheartandfuturetrends AT bukharini advancementsintheoraldeliveryofdocetaxelchallengescurrentstateoftheartandfuturetrends AT hussaini advancementsintheoraldeliveryofdocetaxelchallengescurrentstateoftheartandfuturetrends AT webstertj advancementsintheoraldeliveryofdocetaxelchallengescurrentstateoftheartandfuturetrends AT shahnazg advancementsintheoraldeliveryofdocetaxelchallengescurrentstateoftheartandfuturetrends
_version_	1718399562696097792

Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends

Ejemplares similares